Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

Leukemia

Volumn 29, Issue 3, 2015, Pages 689-695

  Ferrero, S ^a   Ladetto, M ^a   Drandi, D ^a   Cavallo, F ^a,b   Genuardi, E ^a   Urbano, M ^a   Caltagirone, S ^a   Grasso, M ^b   Rossini, F ^b   Guglielmelli, T ^b   Cangialosi, C ^b   Liberati, A M ^b   Callea, V ^b   Carovita, T ^b   Crippa, C ^b   De Rosa, L ^b   Pisani, F ^b   Falcone, A P ^b   Pregno, P ^b   Oliva, S ^a,b   Terragna, C ^b   Musto, P ^b   Passera, R ^a   Boccadoro, M ^a,b   Palumbo, A ^a,b   more..

^a UNIVERSITY OF TURIN   (Italy)

^b GIMEMA Italian Myeloma Network   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN HEAVY CHAIN; PYRAZINE DERIVATIVE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; FOLLOW UP; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETREATMENT; ADULT; AGED; AUTOTRANSPLANTATION; CLINICAL TRIAL; FEMALE; GENE EXPRESSION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PYRAZINES; RECURRENCE; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84924536232     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.219     Document Type: Article

References (24)

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
3. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612-2624.
4. Paiva B, Vidriales MB, Cerveró J, Mateo G, Pérez JJ, Montalbán MA et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112: 4017-4023.
5. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077-2084.
6. Terragna C, Zamagni E, Petrucci MT, Durante S, Patriarca F, Narni F et al. Molecular remission after bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone as consolidation therapy following double autologous transplantation for multiple myeloma: results of a qualitative and quantitative analysis. [abstract]. Blood 2010; 116: abstract 861.
7. Korthals M, Sehnke N, Kronenwett R, Bruns I, Mau J, Zohren F et al. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter. Biol Blood Marrow Transplant 2012; 18: 423-431.e3.
8. Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MÁ, Martínez-López J et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119: 687-691.
9. Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 398-404.
10. Ladetto M, Ferrero S, Drandi D, Omedè P, Patriarca F, Mordini N et al. High rates of prolonged molecular remissions after tandem autologous-nonmyeloablative allografting in newly diagnosed myeloma. ASH Annu Meet Abstr 2012; 120: 4204.
11. Korthals M, Sehnke N, Kronenwett R, Schroeder T, Strapatsas T, Kobbe G et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 1109-1115.
12. Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García Het al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A Comparative Analysis with Flow Cytometry. Leukemia 2014; 28: 391-397.
13. Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11: 1793-1798.
14. Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 241-253.
15. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604-611.
16. Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011; 118: 3205-3211.
17. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009; 27: 4365-4370.
18. Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger Met al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120: 5185-5187.
19. Ferrero S, Monitillo L, Mantoan B, Barbero D, Genuardi E, Barbiero S et al. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. Ann Hematol 2013; 92: 1503-1511.
20. Ferrero S, Drandi D, Mantoan B, Ghione P, Omedè P, Ladetto M. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. Hematol Oncol 2011; 29: 167-176.
21. Martinez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala Ret al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014; 123: 3073-3079.
22. Vij R, Mazumder A, Klinger M, O'Dea D, Paasch J, Martin T et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin Lymphoma Myeloma Leuk 2014; 14: 131-139.e1.
23. Ladetto M, Brüggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2013; 28: 1299-1307.
24. Martinez-Lopez J, Fulciniti M, Barrio S, Carlton V, Moorhead M, Lahuerta JJ et al. Deep sequencing reveals oligoclonality at the immunoglobulin locus in multiple myeloma patients. [abstract]. Blood 2013; 122: 401.